314 related articles for article (PubMed ID: 23843495)
1. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000).
Radford J; Davies A; Cartron G; Morschhauser F; Salles G; Marcus R; Wenger M; Lei G; Wassner-Fritsch E; Vitolo U
Blood; 2013 Aug; 122(7):1137-43. PubMed ID: 23843495
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.
Grigg A; Dyer MJ; Díaz MG; Dreyling M; Rule S; Lei G; Knapp A; Wassner-Fritsch E; Marlton P
Haematologica; 2017 Apr; 102(4):765-772. PubMed ID: 28011903
[TBL] [Abstract][Full Text] [Related]
3. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
[TBL] [Abstract][Full Text] [Related]
4. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Diefenbach C; Kahl BS; McMillan A; Briones J; Banerjee L; Cordoba R; Miall F; Burke JM; Hirata J; Jiang Y; Paulson JN; Chang YM; Musick L; Abrisqueta P
Lancet Haematol; 2021 Dec; 8(12):e891-e901. PubMed ID: 34826412
[TBL] [Abstract][Full Text] [Related]
5. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
Hiddemann W; Barbui AM; Canales MA; Cannell PK; Collins GP; Dürig J; Forstpointner R; Herold M; Hertzberg M; Klanova M; Radford J; Seymour JF; Tobinai K; Trotman J; Burciu A; Fingerle-Rowson G; Wolbers M; Nielsen T; Marcus RE
J Clin Oncol; 2018 Aug; 36(23):2395-2404. PubMed ID: 29856692
[TBL] [Abstract][Full Text] [Related]
6. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
Vitolo U; Trněný M; Belada D; Burke JM; Carella AM; Chua N; Abrisqueta P; Demeter J; Flinn I; Hong X; Kim WS; Pinto A; Shi YK; Tatsumi Y; Oestergaard MZ; Wenger M; Fingerle-Rowson G; Catalani O; Nielsen T; Martelli M; Sehn LH
J Clin Oncol; 2017 Nov; 35(31):3529-3537. PubMed ID: 28796588
[TBL] [Abstract][Full Text] [Related]
7. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
[TBL] [Abstract][Full Text] [Related]
8. Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial.
Brown JR; O'Brien S; Kingsley CD; Eradat H; Pagel JM; Lymp J; Hirata J; Kipps TJ
Blood; 2015 Apr; 125(18):2779-85. PubMed ID: 25769620
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.
Tilly H; Morschhauser F; Casasnovas O; Molina TJ; Feugier P; Gouill SL; Haioun C; Tournilhac O; Bouabdallah R; Gabarre J; Lamy T; Cabeçadas J; Becker S; Jardin F; Mounier N; Salles G;
Lancet Haematol; 2018 Sep; 5(9):e403-e410. PubMed ID: 30172345
[TBL] [Abstract][Full Text] [Related]
10. Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.
Sharman JP; Forero-Torres A; Costa LJ; Flinn IW; Inhorn L; Kelly K; Bessudo A; Fayad LE; Kaminski MS; Evens AM; Flowers CR; Sahin D; Mundt KE; Sandmann T; Fingerle-Rowson G; Vignal C; Mobasher M; Zelenetz AD
Leuk Lymphoma; 2019 Apr; 60(4):894-903. PubMed ID: 30277102
[TBL] [Abstract][Full Text] [Related]
11. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.
Federico M; Luminari S; Dondi A; Tucci A; Vitolo U; Rigacci L; Di Raimondo F; Carella AM; Pulsoni A; Merli F; Arcaini L; Angrilli F; Stelitano C; Gaidano G; Dell'olio M; Marcheselli L; Franco V; Galimberti S; Sacchi S; Brugiatelli M
J Clin Oncol; 2013 Apr; 31(12):1506-13. PubMed ID: 23530110
[TBL] [Abstract][Full Text] [Related]
12. Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States.
Guzauskas GF; Masaquel A; Thuresson PO; Dawson K; Veenstra DL
Leuk Lymphoma; 2019 Jul; 60(7):1668-1676. PubMed ID: 30632837
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma.
Wilder DD; Ogden JL; Jain VK
Clin Lymphoma; 2002 Mar; 2(4):229-37. PubMed ID: 11970762
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
Trotman J; Barrington SF; Belada D; Meignan M; MacEwan R; Owen C; Ptáčník V; Rosta A; Fingerle-Rowson GR; Zhu J; Nielsen T; Sahin D; Hiddemann W; Marcus RE; Davies A;
Lancet Oncol; 2018 Nov; 19(11):1530-1542. PubMed ID: 30309758
[TBL] [Abstract][Full Text] [Related]
15. An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma.
Morschhauser F; Salles G; Le Gouill S; Tilly H; Thieblemont C; Bouabdallah K; Fabiani B; Ménard C; Tarte K; Cartron G; Houot R
Blood; 2018 Oct; 132(14):1486-1494. PubMed ID: 30068505
[TBL] [Abstract][Full Text] [Related]
16. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
Cheson BD; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben JG; Lennard A; Lugtenburg PJ; Fingerle-Rowson G; Mattiello F; Knapp A; Sehn LH
J Clin Oncol; 2018 Aug; 36(22):2259-2266. PubMed ID: 29584548
[TBL] [Abstract][Full Text] [Related]
17. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
18. Safe administration of rituximab for follicular lymphoma after obinutuzumab infusion-related reaction.
Hara T; Suzuki R; Ohno A; Yamakawa K; Yamagishi Y; Sugiyama Y; Sobajima T; Yamada R; Matsumoto R; Ikeda Y; Murayama M; Tsurumi H
Int J Hematol; 2020 Apr; 111(4):585-590. PubMed ID: 31848991
[TBL] [Abstract][Full Text] [Related]
19. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study.
Nowakowski GS; LaPlant B; Habermann TM; Rivera CE; Macon WR; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Klebig RR; Reeder CB; Witzig TE
Leukemia; 2011 Dec; 25(12):1877-81. PubMed ID: 21720383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
